Médecine

Paramédical

Autres domaines


Suscribirse

Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment - 28/08/20

Doi : 10.1016/j.biopha.2020.110500 
Siyi Xin a, 1 , Xueqi Cheng a, 1 , Bo Zhu a , Xiaolong Liao a , Feng Yang a , Lina Song a , Yan Shi b , Xuefeng Guan b , Renyi Su a , Jian Wang a , Limin Xing a , Xiping Xu a , Lin Jin a , Yanping Liu a , Wei Zhou a , Dongwei Zhang c , Liang Liang c , You Yu d , Rui Yu b,
a Xiangyang NO.1 People’s Hospital, Affiliated Hospital of Hubei University of Medicine, Xiangyang, Hubei, 441000, China 
b Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, 110847, China 
c The First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, 110031, China 
d The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, 110034, China 

Corresponding author at: Department of Science and Technology, Liaoning University of Traditional Chinese Medicine, 79 Chongshan E Rd, Jin Lang Shang Quan, Huanggu District, Shenyang, Liaoning, 110847, China.Department of Science and TechnologyLiaoning University of Traditional Chinese Medicine79 Chongshan E RdJin Lang Shang QuanHuanggu DistrictShenyangLiaoning110847China

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Graphical abstract




El texto completo de este artículo está disponible en PDF.

Highlights

Qingfeng Paidu decoction + Western medicine are beneficial for COVID-19.
Combined therapy improves anti-inflammation in patients with COVID-19.
Combined therapy may mitigate the extent of multi-organ impairment in COVID-19.
Mortality rate and length of stay were unaffected by Qingfeng Paidu decoction.

El texto completo de este artículo está disponible en PDF.

Abstract

Background

Coronavirus disease 2019 (COVID-19)2 has emerged as a global pandemic. However, as effective treatments for this disease are still unclear, safe and efficient therapies are urgently needed. Qingfei Paidu decoction (QPD)3 is strongly recommended in the Chinese Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Provisional 6th Edition). However, clinical research data on the effects of QPD on COVID-19 are scarce. Our study aimed to explore the effects of combined treatment with QPD and Western medicine on COVID-19.

Methods

In this study, 63 patients with confirmed COVID-19 were analyzed. During the first 14 days of hospitalization, patients with deteriorating symptoms were administered QPD along with Western medicine therapy (the antiviral medicine selected from interferon, lopinavir, or arbidol). The clinical characteristics and blood laboratory indices (blood routine, inflammatory factors, and multi-organ biochemical indices) were examined, and the total lung severity scores were evaluated in each patient by reviewing chest computed tomography before treatment and at the end of treatment.

Results

Before QPD treatment, the combined treatment group showed higher blood C-reactive protein levels and more severe pulmonary inflammation and clinical symptoms than the Western medicine treatment group. Both groups met the discharge criteria after a similar length of hospitalization. At the end of treatment, circulating white blood cells, total lymphocyte count, and glutamic-oxaloacetic transaminase levels improved dramatically in both groups (P <  0.05). In contrast, C-reactive protein, creatine kinase, creatine kinase-myocardial band, lactate dehydrogenase, and blood urea nitrogen levels were improved only in the combined treatment group (P <  0.05), and C-reactive protein and creatine kinase were the most pronounced (P <  0.01). Compared with baseline, at the end of treatment, the proportion of patients with normal values of C-reactive protein, total lymphocyte count, and lactate dehydrogenase were increased in the combined treatment group (P < 0.05), whereas no significant difference was observed in the Western medicine treatment group (P >  0.05).

Conclusion

The combination of QPD with Western medicine demonstrated significant anti-inflammatory effects compared with those of only Western medicine in patients with mild and moderate COVID-19; however, neither mortality nor length of hospitalization was affected. Moreover, the combined treatment tended to mitigate the extent of multi-organ impairment. Long-term randomized controlled trials with follow-up evaluations are required to confirm the results presented here.

El texto completo de este artículo está disponible en PDF.

Abbreviations : BUN, CAD, CK, CK-MB, COVID-19, CRE, CRP, CT, cTnI, DM, ESR, GPT, GOT, HBP, LDH, MYO, PCT, QPD, SARS-CoV, SARS-CoV-2, TCM, TLC, WBC, WM

Keywords : COVID-19, Qingfei Paidu decoction, Traditional Chinese medicine, Clinical trials


Esquema


© 2020  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 129

Artículo 110500- septembre 2020 Regresar al número
Artículo precedente Artículo precedente
  • Preparation of microspheres encapsulating sorafenib and catalase and their application in rabbit VX2 liver tumor
  • Xihan Li, Hui Yu, Ying Huang, Yu Chen, Jialun Wang, Lei Xu, Feng Zhang, Yuzheng Zhuge, Xiaoping Zou
| Artículo siguiente Artículo siguiente
  • Amelioration of risk factors associated with diabetic nephropathy in diet-induced pre-diabetic rats by an uracil-derived diimine ruthenium(II) compound
  • Lindokuhle Patience Mabuza, Mlindeli Wilkinson Gamede, Sanam Maikoo, Irvin Noel Booysen, Phikelelani Siphosethu Ngubane, Andile Khathi

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.